Introduction
The use of prescription guidelines with the aim of implementing general therapeutic standards is a common feature in many health care systems [1] . The need for guidelines arises from a general understanding that promoting evidence-based and efficient medical care may reduce unnecessary variations in medical practice and improve quality [2] . Moreover, guidelines may also serve as a "tool" to prescribers who have difficulty assimilating the every-increasing volume of new scientific information [1, [3] [4] [5] . Even though the investigation of adherence to guidelines is attracting increasing interest, just which factors at different levels of the health care organization condition adherence to guidelines-and how (mechanism) they do this-are insufficiently understood [6] [7] [8] [9] .
In Sweden, each county council has a therapeutic committee responsible for the issuing of evidence-based guidelines [10, 11] . Despite these recommendations, several studies have demonstrated substantial and unexplained differences in the adherence to guidelines among physicians and among health care centres (HCC) [8, 9, 12, 13] .These differences may express themselves as a clustering of similar prescription behaviour among physicians at the same HCC and suggest the existence of local therapeutic traditions. Quantifying and understanding this variation is relevant to the planning of interventions aimed at improving the quality of drug prescribing behavour.
In the region of Skåne, Sweden, the implementation of a decentralized drug budget was found to increase adherence to guidelines and promote efficient drug therapy [9] . Similarly, in 2003, in Skaraborg, Sweden, the economic responsibility for tax-financed drug costs was transferred from the regional administrative level to the local HCC. However, the effects of this intervention are still unknown. In the study reported here, we used multilevel regression analyses (MLRA) and data from the Skaraborg Primary Care Database (SPCD) [14] to evaluate the effect of this decentralized drug budget. We focused on adherence to statin (HMG-CoA reductase inhibitors) prescriptions since this group of cholesterol-lowering drugs has very homogeneous indications and similar efficacy which nearly eliminates the possibility of confounding by indication and patient mix when different practices and physicians are compared. An additional aim was to disentangle the relevance of different levels (i.e. patients, physicians, HCCs) in order to gain a better understanding of adherence with guidelines. Based on results from previous studies [9] , our hypothesis was that the decentralized budget would result in an increased prevalence and a decreased variance between physicians and between HCCs in terms of the prescription of recommended statins.
Materials and methods
The Skaraborg Primary Care Database Skaraborg, one of four administrative areas of the region of Västra Götaland, situated in the southwest of Sweden, is mostly rural and inhabited by approximately 250,000 individuals within 15 municipalities. Inpatient care is provided by three public hospitals and primary care by 24 public and one private HCC as well as by a few private solo practitioners. About 250,000 office visits are registered at the public HCCs each year. Approximately 75% of all drug prescriptions are issued outside the hospitals, 85% of these at public HCCs.
The SPCD was implemented in 2000 and is based on a common computerized medical journal used by all the 24 publicly administrated HCCs in the area. Among the information compiled in SPCD is all data on drug prescriptions, laboratory tests and current diagnosis at every consultation. By means of a unique anonymized identification number, the SPCD is able to identify the HCC, the physician and the patient.
Study population
From the SPCD, we identified all patients with at least one prescription of statin, defined according to the Anatomical Therapeutical Chemical (ATC) classification system code C10AA [15] . We then selected two datasets: (1) 
Individual-level variables
The outcome variable was the prescription of recommended statin (yes vs. no). In the 2003 dataset, these drugs were simvastatin (Zocord or generic simvastatin) and pravastatin (Pravachol); in the 2005 dataset, only simvastatin (Zocord or generic simvastatin) was recommended. We categorized the age of the patients into four age groups: <54, 55-64, 65-74 and 75+ years and used the youngest group as the reference in the comparisons. We included the sex of the patients as a dummy variable, using women as the reference in the analysis. Based on the actual evidence, neither age nor sex nor any other patient characteristic should motivate the preferential prescription of a specific statin over another. Therefore, the inclusion of individual-level variables in the analysis was not motivated by the need of adjustment for confounding but, rather, because we wanted to gain an understanding of the importance of these factors in the prescribing process.
Physician-level variables
The results of previous studies have shown that prescription behaviour is influenced by prescriber characteristics. We therefore included the physician's occupational status in the analysis, categorized as intern, resident, general practitioner or locum. Each category was split into two groups according to the median age of the specific group (Table 1) . Of the eight different groups, older GPs were used as the reference in the analysis. We included the sex of the physician as a dummy variable, using women as the reference in the analyses. However, information on physician's characteristics was only available for the 2005 dataset.
Multi-level regression models
We used MLRA [16, 17] to estimate the probability of prescribing a recommended statin while accounting for the hierarchical structure of the data (i.e., patients nested within physicians nested within HCCs). We developed three consecutive models (A, B, C) for dataset 2003 and four models (A, B, C and D) for dataset 2005. Model A was an empty twolevel model that included only patients and HCCs as random effects. Model B was a three-level model in which patients were nested within physicians that were in turn nested within HCCs. Model C included the patient characteristics and Model D included both patient and physician characteristics. Using this approach, our aim was to investigate whether the individual and contextual characteristics could explain the residual variation between physicians and between HCCs. We estimated odds ratios (OR) and 95% credible intervals (95% CI) from the models. Model fit was evaluated by comparing change in the deviance information criteria (DIC).
In the random-effects part of the multilevel analysis, we obtained the variance and 95% credible intervals at the physician and HCC levels and used this information to calculate the median odds ratio (MOR) and 95% credible intervals [16] [17] [18] [19] . The MOR translates the variance into the OR scale and is thereby comparable with the OR of the individual or area variables. The MOR can be interpreted as the amount by which the odds of a randomly selected patient receiving a recommended statin would increase (in The study was approved by The Regional Ethical Review Board in Gothenburg. Table 1 indicates that overall the prevalence of adherence to guidelines for the prescription of statins increased from 77% in 2003 to 84% in 2005 (relative ratio 1.09, 95% CI 1.01-1.19). In 2003, older patients had a higher adherence to guidelines, but these age differences disappeared in 2005. Men were prescribed statins more often than women, but there were no gender-related differences in the prescription of the recommended drugs. In 2005, 68% of all the statins were prescribed by male doctors who also showed a slightly lower percentage of prescribing the recommended statins than their female colleagues. Young interns showed the highest adherence to the guidelines (90%), and older locums the lowest (77%). Multilevel regression analysis Table 2 shows the association between patient and physician characteristics and the prescription of recommended statins according to the MLRA. In 2003, adherence to guidelines increased with the age of the patients, but in 2005, there were no differences between age groups. Older locum physicians had a lower probability of prescribing a recommended statin than older GPs Model A in Table 3 only includes two levels (i.e., patients and HCCs) and shows that a randomly selected patient's median odds ratio of receiving a recommended statin would increase 2.14-fold in 2003 (MOR HCC2003 =2.14 ) and 1.37-fold in 2005 (MOR HCC2005 =1.37) if he/she moved to an HCC with a higher adherence to guidelines.
Results
Model B in Table 3 includes three levels and shows that the HCC and physician levels accounted for approx- 
Discussion
The results of our investigation indicate that transferring the economic responsibility from the central health care authorities at the County Council to the local HCCs seems to have improved adherence to statin prescription guidelines. The use of recommended statins increased from 77% in 2003 to 84% in 2005, and the variance among HCCs and among physicians decreased during the same period. Our results fully agree with those from a previous analysis performed in the county of Scania [9] . However, our analysis also adds information regarding the physician level. We show that approximately 50% of the higher level variance could be attributed to the physician level, which is in line with other studies [21] . In 2005, after the decentralized budget had been implemented, the differences between HCCs and between physicians became almost negligible and, therefore, the possibility to distribute the variance to different levels of the analysis was limited. This is also illustrated in Fig. 2 by the fact that none of the HCCs and only a few physicians conclusively differed from the overall mean adherence in 2005.
While our analytical approach of focusing on both changes in variance and changes in prevalence has been implemented in other research fields [22] [23] [24] , it has rarely been used for investigating practice variation in pharmacoepidemiology. Observing an increase in the prevalence of prescribing for recommended statins does not necessarily imply an improvement since the variation around the prevalence could be very high. The desired outcome is obviously not only to increase adherence with guidelines but also to eliminate unnecessary practice variation.
An advantage of the MLRA is that it allows the variance in outcome to be disentangled among the different levels of analysis. Using this information for identifying which level could be most relevant for a possible intervention. In 2003, the variance at the higher levels was rather large and equally distributed among HCCs and physicians, indicating that any intervention aimed to improve adherence with guidelines should be focused on both levels simultaneously. The decentralized budget that was implemented was a general intervention towards all HCCs and all physicians that was disseminated through the HCCs. However, it appears to have effectively decreased the variance at both levels, although an intervention directed towards specific HCCs and physicians would theoretically also be effective in reducing variance. In 2005, the higher level variance was very small which suggests that any further intervention directed towards specific HCCs or physicians would render less effective.
In 2005 we observed that older locum physicians had a lower adherence to prescription guidelines than older general practitioners (GPs), which may reflect intrinsic characteristics of this personal category. Locum physicians share the common work environment and the same constraints as other physicians at the HCC, but only for a limited period of time, and therefore might be less affected by the therapeutic traditions acting at the level of the HCC. However, an intervention focusing on locums will possibly not be very efficient [25] since the variance at the physician level (and the corresponding MOR) was negligible. Observational epidemiological studies are often the only option for investigating questions that for practical, economical and/or ethical reasons cannot be analysed by randomized trials [26] [27] [28] [29] . Confounding and selection bias may threaten the validity of the studies. However, because of similar indications and efficacy, statins are an ideal medication group for investigating prescribing behaviour [30] , and there is no rationale for considering patient characteristics as confounding factors when variations in practice are investigated. The value of including individual and physician covariates resides in an understanding of the prescription process. In our investigation, we only considered basic individual variables, such as age and gender of the patient, and our results showed that for the 2003 dataset younger patients had a lower propensity to receive the recommended statins. This prescribing behaviour cannot be justified by any medical argument; rather, it may reflect the influence of constructed social roles and expectations. From the perspective of equity in health care, it is relevant to question the physicians' choice of more expensive-but not more efficient-brands for some groups of patients, given that a large part of this medication expenditure is funded by the public reimbursement system. We cannot exclude the possibility that unmeasured factors-in addition to the decentralized budget-might have influenced the observed results (i.e., increase in prevalence and reduction in variance). It is also possible that the expiration of the Zocord patent in 2003, with the following decline in price for generic simvastatin and increase in cost difference with other statins, may have contributed in the choice of recommended statin. Information campaigns issued by the local therapeutic committee and the growing awareness of rising costs for medication are other possible contributing factors.
Most patients receive statins as a long-term therapy. However, according to Swedish law, a prescription cannot be issued for a period longer than 1 year. Therefore, in routine care, repeat prescriptions are sometimes issued by phone and eventually by a different physician. We have attempted to identify homogeneous physician-patient relations by only including patients with all cardiovascular prescriptions by the same physician. However, we cannot exclude a delayed effect of the decentralized budget conditioned by the fact that while new users are prescribed the recommended drugs, the change to the recommended drugs is relatively slow for continuous users, especially if the repeated prescription is written by another physician.
Our study investigates statin prescription in primary health care. Therefore, our results are not directly applicable to those drug prescribed for patients under hospital care. Older patients treated in municipal homecare facilities are also excluded since their prescriptions are not registered in the database. However, a study of statin treatment in a local community in Skaraborg showed that very few elderly (85+ years) used statins [31] .
The period of our analyses was relatively short, so the phenomenon of an immediate positive response followed by a later gradual return to the pre-intervention situation cannot be excluded. Therefore, in order to obtain some information on the effect of the intervention beyond 2005, we also analysed the prevalence of recommended statins in the time period from July 2008 to December 2009. At the moment of the analyses, this dataset was not complete (i.e., it included only 23 of 24 HCCs, and there was no information on prescribers), and we did not include it in the main multilevel analysis. This analysis did indicate that the overall prevalence of recommended statin prescriptions in 2008-2009 was 89%, suggesting that the effects of the intervention were stable (analyses available on request).
Practice variation is a common phenomenon that is not necessarily inappropriate; rather, it may reflect different therapeutic approaches to a similar health problem [32] . However, a situation in which the prescriber selects the more costly option when the same pharmacological therapy is available as different brands at different prices provides the basis for questioning the suitability of the observed practice variation.
In conclusion, the results of our study suggest that decentralization of the drug budget to the HCCs, i.e., transferring the economic responsibility and the power-in terms of management and decision-making-to the HCCs, seemed to have been an appropriate intervention for reducing inefficient therapeutic traditions. As a natural consequence, adherence to the drug committee's recommendations increased, and differences between physicians and between HCCs decreased.
